Top

World Journal of Surgery

Published in:

01-02-2016 | Original Scientific Report

Neutrophil–Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection

Authors: Yusuke Takahashi, Masafumi Kawamura, Tai Hato, Masahiko Harada, Noriyuki Matsutani, Hirotoshi Horio

Published in: World Journal of Surgery | Issue 2/2016

Abstract

Backgrounds

The neutrophil–lymphocyte ratio (NLR) is a simple and low-cost index that may be a benchmark for systemic inflammatory response and antitumor immunity. The goal of the study was to investigate the prognostic value of preoperative NLR in patients with lung adenocarcinoma after complete resection.

Methods

The subjects were 361 consecutive patients with lung adenocarcinoma who underwent complete resection between 2000 and 2009. Perioperative clinical and laboratory data were evaluated retrospectively. The cohort was divided using the cut-off value for preoperative NLR identified in receiver operating characteristic analysis. Correlations of NLR with clinicopathological characteristics and prognosis were examined.

Results

A high NLR was significantly correlated with a smoking history >10 pack-years (p = 0.023), pathological stage II or III (p < 0.001), lymphatic invasion (p = 0.003), and pleural invasion (p = 0.039). In univariate analysis, the high NLR group had significantly lower 5-year overall survival (86.0 vs. 77.1 %, p < 0.001) and 5-year recurrence-free survival (75.1 vs. 59.9 %, p < 0.001). Multivariate analysis showed that NLR was an independent prognostic factor (hazard ratio 1.822, 95 % confidence interval 1.133–2.931, p = 0.013).

Conclusion

These results show that preoperative NLR is an independent prognostic factor in patients with lung adenocarcinoma after complete resection. NLR may reflect host immunity and systemic inflammation that facilitates tumor growth.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE 7:e40109PubMedPubMedCentralCrossRef

Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry (2008) A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 3:46–52PubMedCrossRef

Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA (2011) Non-small-cell lung cancer. Lancet non-small-cell lung cancer. Lancet 378:1727–1740PubMedCrossRef

Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil and lymphocyte ratio predicts survival in patients with various cancer. Br J Cancer 107:695–699PubMedPubMedCentralCrossRef

D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F (2015) PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112:95–102PubMedPubMedCentralCrossRef

Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K (2005) Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 48:281–289PubMedCrossRef

Sun PL, Jin Y, Kim H, Seo AN, Jheon S, Lee CT, Chung JH (2013) Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch 463:427–436PubMedCrossRef

Black CC, Turk MJ, Dragnev K, Rigas JR (2013) Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung 191:265–270PubMedCrossRef

10.

Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, Konaka C, Kato H (2002) Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37:161–169PubMedCrossRef

11.

Travis WDBE, Mueller-Hermelink HK, Harris CC (eds) (2002) World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon

12.

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706–714PubMedCrossRef

13.

Graziosi L, Marino E, De Angelis V, Rebonato A, Cavazzoni E, Donini A (2015) Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer. Am J Surg 209:333–337PubMedCrossRef

14.

Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, Du C, Wang S, Wei B, Fu P (2014) Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Oncol Targets Ther 7:1743–1752

15.

Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184–190PubMed

16.

Ben Q, An W, Wang L, Wang W, Yu L, Yuan Y (2015) Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Pancreas 44:471–477PubMed

17.

Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108:901–907PubMedPubMedCentralCrossRef

18.

Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, Glehr M, Zacherl M, Stojakovic T, Gerger A, Leithner A (2013) Elevated preoperative neutrophil/lymphocyte ratio is associated with prognosis in soft-tissue sarcoma patients. Br J Cancer 108:1677–1683PubMedPubMedCentralCrossRef

19.

Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA (2014) Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer 110:1930–1935PubMedPubMedCentralCrossRef

20.

Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425–428PubMedCrossRef

21.

Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2011) Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 31:2995–2998PubMed

22.

Takahashi Y, Horio H, Hato T, Harada M, Matsutani N, Morita S, Kawamura M (2015) Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage I non-small cell lung cancer after complete resection. Ann Surg Oncol. doi:10.1245/s10434-015-4735-5, Jul 22 2015)

23.

Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659:15–30PubMedCrossRef

24.

Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457–465PubMed

25.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef

26.

Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect–a histopathological and immunohistochemical study. BMC Cancer 1:7PubMedPubMedCentralCrossRef

27.

Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF (1999) Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 159:857–863PubMedCrossRef

28.

Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small cell lung cancer: an analysis of japan Multinational Atrial Organization LC00-03. Eur J Cancer 45:1950–1958PubMedCrossRef

29.

Roxburg CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149–163CrossRef

30.

Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Cho GY, Chae IH, Choi DJ (2013) Prognostic value of neutrophil to lymphocyte ratio in patients presenting ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 11:55–59

31.

Sen N, Afsar B, Ozcan F, Buyukkaya E, Isleyen A, Akcay AB, Yuzgecer H, Kurt M, Karakas MF, Basar N, Hajro E, Kanbay M (2013) The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 228:203–210PubMedCrossRef

32.

Kocyigit I, Eroglu E, Unal A, Sipahioglu MH, Tokgoz B, Oymak O, Utas C (2013) Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol 26:358–365PubMedCrossRef

33.

Spark JI, Sarveswaran J, Blest N, Charalabidis P, Asthana S (2010) An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia. J Vasc Surg 52:632–636PubMedCrossRef

34.

Gökhan S, Ozhasenekler A, Mansur Durgun H, Akil E, Ustündag M, Orak M (2013) Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. Eur Rev Med Pharmacol Sci 17:653–657PubMed

35.

Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T (2012) Elevated preoperative inflammatory markers based on neutrophil-to lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 32:3535–3538PubMed

36.

Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K (2010) Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol 5:1136–1142PubMedCrossRef

37.

Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H (2014) Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Oncol Targets Ther 7:567–573CrossRef

38.

Kinoshita T, Ishii G, Hiraoka N, Hirayama S, Yamauchi C, Aokage K et al (2013) Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma. Cancer Sci 104:409–415PubMedCrossRef

39.

Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M, Adusumilli PS (2013) Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 31:490–498PubMedPubMedCentralCrossRef

40.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2013) Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 11:645–653PubMed

41.

Kwon MJ, Seo J, Kim YJ, Kwon MJ, Choi JY, Kim TE, Lee DH, Park S, Shin YK, Han J, Choi YL (2013) Prognostic significance of CD151 overexpression in non-small cell lung cancer. Lung Cancer 81:109–116PubMedCrossRef

Title: Neutrophil–Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection
Authors: Yusuke Takahashi
Masafumi Kawamura
Tai Hato
Masahiko Harada
Noriyuki Matsutani
Hirotoshi Horio
Publication date: 01-02-2016
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 2/2016
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-015-3275-2

At a glance: The STEP trials

Springer Medicine

Neutrophil–Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection

Abstract

Backgrounds

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Backgrounds

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

Severe Complications of Laparoscopic and Conventional Appendectomy Reported to the Finnish Patient Insurance Centre

The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach

Important Treatment Modalities for Symptomatic Malignant Pericardial Effusions

Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study

Single-Port VATS: The New Paradigm

High Ligation of the Anal Fistula Tract by Lateral Approach